
1. Technology overview
Vitestro is a Dutch medtech company with its address at Europalaan 500, 3526 KS Utrecht, the Netherlands. It develops Aletta, described as the first Autonomous Robotic Phlebotomy Device, which automates diagnostic blood collection in hospitals and laboratories.
Aletta identifies a vein, performs the blood draw and applies a bandage without a phlebotomist handling the needle. A peer-reviewed study in Clinical Chemistry reported a 94.5% first-stick success rate. The device has had CE marking since August 2024, and Dutch hospitals and labs such as St. Antonius, Deventer Ziekenhuis and Amsterdam UMC are listed as users.
2. Highlighted features & specifications
- Vein identification: the robot locates a suitable vein autonomously.
- Autonomous draw: performs the blood collection without manual needle handling.
- Bandage application: applies a bandage after the draw.
- Clinical evidence: 94.5% first-stick success in a peer-reviewed Clinical Chemistry study.
- Regulatory status: CE marking since 2024 and FDA De Novo authorization in 2026.
3. Potential application
Large Vietnamese hospitals and diagnostic chains could pilot the robot in central outpatient blood collection areas. Health check centers with high morning throughput could use it to standardize draws and reduce repeat punctures.
4. Benefits
Reports a 94.5% first-stick success rate in a peer-reviewed study. Automates a high-volume routine task, supporting laboratory workflows and relieving phlebotomy staff. The device holds CE marking (August 2024) and FDA De Novo authorization (August 2026), and has been ordered by Odense University Hospital in Denmark.
5. Market trends & opportunities
Hospitals and laboratories face phlebotomist shortages and rising diagnostic testing volumes, which drives interest in automating routine blood collection. Vietnamese hospitals and large diagnostic lab chains with high daily blood draw volumes are a potential fit, though local regulatory registration would be needed.
6. Other information
Utrecht, the Netherlands. 70 million USD oversubscribed Series B announced 10 March 2026; CE marking 28 August 2024; FDA De Novo 20 August 2026. Hospitals and labs listed: OLVG Lab, Result laboratorium, St. Antonius, Deventer Ziekenhuis, Amsterdam UMC, Odense University Hospital.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































